Alan Bye
Impact in
- Virology top 5%
- Pharmaceutical Science top 2%
Papers in
- Pharmacology 17
- Antibiotics Pharmacokinetics and Efficacy 9
- Pharmacogenetics and Drug Metabolism 7
-
- Analytical Methods in Pharmaceuticals 12
- Co-authors
- Lindsey Cass (5 shared papers)Constantin Efthymiopoulos (3 shared papers)Alison E. Mackie (9 shared papers)L.F. Lacey (6 shared papers)Oliver N. Keene (5 shared papers)G. Land (8 shared papers)Katy H. P. Moore (2 shared papers)F. G. Bell (2 shared papers)
- Journals
- Clinical Pharmacokinetics (10 papers)European Journal of Clinical Pharmacology (6 papers)British Journal of Clinical Pharmacology (5 papers)Antimicrobial Agents and Chemotherapy (4 papers)Pharmaceutical Research (3 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Alan Bye
90 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 153
- Virology 124
- Pharmaceutical Science 156
- Pharmacology 187
- Infectious Diseases 347
- Epidemiology 589
Countries citing papers authored by Alan Bye
This map shows the geographic impact of Alan Bye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Bye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Bye more than expected).
Fields of papers citing papers by Alan Bye
This network shows the impact of papers produced by Alan Bye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Bye. The network helps show where Alan Bye may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Bye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1999 | 235 | |
| 2 | 1999 | 178 | |
| 3 | 1999 | 109 | |
| 4 | 1997 | 107 | |
| 5 | 2002 | 92 | |
| 6 | 2001 | 87 | |
| 7 | 1994 | 73 | |
| 8 | 2002 | 72 | |
| 9 | 1996 | 70 | |
| 10 | 1995 | 70 | |
| 11 | 2011 | 55 | |
| 12 | 2000 | 54 | |
| 13 | 1999 | 53 | |
| 14 | 1980 | 51 | |
| 15 | 1996 | 49 | |
| 16 | 2000 | 48 | |
| 17 | 1985 | 48 | |
| 18 | 1986 | 44 | |
| 19 | 1996 | 44 | |
| 20 | 1981 | 43 |
About Alan Bye
Alan Bye is a scholar working on Pharmacology, Pharmacology, Analytical Chemistry, Molecular Biology and Infectious Diseases, having authored 91 papers that have together received 2.7k indexed citations. Recurring topics across this work include Analytical Methods in Pharmaceuticals (12 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers), HIV/AIDS drug development and treatment (9 papers), Inhalation and Respiratory Drug Delivery (7 papers), Pharmacogenetics and Drug Metabolism (7 papers), Pharmaceutical studies and practices (7 papers), Mining Techniques and Economics (7 papers) and Statistical Methods in Clinical Trials (7 papers). The work is most often cited by research in Virology (124 citations), Pharmaceutical Science (156 citations), Pharmacology (187 citations), Infectious Diseases (347 citations) and Epidemiology (589 citations). Alan Bye has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Lindsey Cass, Constantin Efthymiopoulos, Alison E. Mackie, L.F. Lacey, Oliver N. Keene, G. Land, Katy H. P. Moore, F. G. Bell, Mark Johnson and Geoffrey J. Yuen. Their work appears in journals such as Clinical Pharmacokinetics, European Journal of Clinical Pharmacology, British Journal of Clinical Pharmacology, Antimicrobial Agents and Chemotherapy and Pharmaceutical Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.